Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Colorcon
McKinsey
Baxter

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR CARBAGLU


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Carbaglu

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00843921 ↗ N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia Active, not recruiting Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2/Phase 3 2008-08-01 This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu┬«) will enhance the ability of the liver to dispose of toxic ammonia which accumulates in several metabolic diseases including urea cycle disorders and organic acid disorders.
NCT00843921 ↗ N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia Active, not recruiting Mendel Tuchman Phase 2/Phase 3 2008-08-01 This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu┬«) will enhance the ability of the liver to dispose of toxic ammonia which accumulates in several metabolic diseases including urea cycle disorders and organic acid disorders.
NCT01341379 ↗ Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate Withdrawn Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 2010-12-01 Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors of metabolism. The investigators propose to determine if short-term (3 day) treatment with N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients. The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators would consider more extensive long-term studies of the drug.
NCT01341379 ↗ Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate Withdrawn Children's Hospital of Philadelphia Phase 2 2010-12-01 Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors of metabolism. The investigators propose to determine if short-term (3 day) treatment with N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients. The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators would consider more extensive long-term studies of the drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Carbaglu

Condition Name

Condition Name for Carbaglu
Intervention Trials
Methylmalonic Acidemia 4
Propionic Acidemia 3
Inborn Errors of Metabolism 2
Carbamoyl-Phosphate Synthase I Deficiency Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Carbaglu
Intervention Trials
Propionic Acidemia 5
Acidosis 5
Amino Acid Metabolism, Inborn Errors 4
Metabolism, Inborn Errors 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Carbaglu

Trials by Country

Trials by Country for Carbaglu
Location Trials
United States 14
Taiwan 1
Saudi Arabia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Carbaglu
Location Trials
District of Columbia 3
Pennsylvania 2
Ohio 2
Massachusetts 2
Colorado 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Carbaglu

Clinical Trial Phase

Clinical Trial Phase for Carbaglu
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Carbaglu
Clinical Trial Phase Trials
Completed 2
Enrolling by invitation 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Carbaglu

Sponsor Name

Sponsor Name for Carbaglu
Sponsor Trials
Mendel Tuchman 3
Children's Hospital of Philadelphia 3
University Hospitals Cleveland Medical Center 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Carbaglu
Sponsor Trials
Other 26
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Express Scripts
Medtronic
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.